Irene Cacciola

Prof. Dr. Irene Cacciola

Department of Clinical and Experimental Medicine, University of Messina, Messina, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Irene CacciolaIrene Cacciola
Irene Cacciola
TPTeresa Pollicino
Teresa Pollicino
GSGiovanni Squadrito
Giovanni Squadrito
GCGiovanni Cerenzia
Giovanni Cerenzia
MOMaria Elena Orlando
Maria Elena Orlando
GRGiovanni Raimondo
Giovanni Raimondo
Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known. With the polymerase chain reaction, we searched for HBV DNA in liver and serum samples from 200 HBsAg-negative patients with hepatitis C virus (HCV)–related liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). One hundred of the patients had detectable antibodies to the HBV core antigen (anti-HBc); 100 were negative for all HBV markers. Eighty-three were treated with interferon alfa. We also studied 50 patients with liver disease who were negative both for HBsAg and for HCV markers. In six patients found to have occult HBV infection, we evaluated possible genomic rearrangements through cloning or direct sequencing procedures. Sixty-six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C (14 percent, P=0.01). Among the 66 patients, 46 were anti-HBc–positive and 20 were negative for all HBV markers (P<0.001). Twenty-two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent, P=0.04). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective (P=0.06). None of the sequenced HBV genomes had changes known to interfere with viral activity and gene expression. Occult hepatitis B infection occurs frequently in patients with chronic hepatitis C liver disease and may have clinical significance.

1 January 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
GRGiovanni Raimondo
Giovanni Raimondo
TPTeresa Pollicino
Teresa Pollicino
Irene CacciolaIrene Cacciola
Irene Cacciola
GSGiovanni Squadrito
Giovanni Squadrito

1 January 2004 in Gastroenterology
Verified
Journal Article
Open access
PDF file
TPTeresa Pollicino
Teresa Pollicino
GSGiovanni Squadrito
Giovanni Squadrito
GCGiovanni Cerenzia
Giovanni Cerenzia
Irene CacciolaIrene Cacciola
Irene Cacciola
GRGiuseppina Raffa
Giuseppina Raffa
GRGiovanni Raimondo
Giovanni Raimondo
Math Eq: Occult hepatitis B virus (HBV) infection is characterized by persistence of HBV DNA into the tissue of hepatitis B surface antigen-negative individuals. The clinical relevance of this peculiar infection is still under debate. In particular, the impact of occult HBV infection in cases of hepatocellular carcinoma (HCC) is uncertain. We investigated the prevalence and molecular status of occult HBV in patients with HCC. Math Eq: We tested tumor tissues from 107 patients with HCC and the corresponding nontumor liver tissue from 72 of these patients for HBV DNA. We also examined liver specimens from 192 patients with chronic hepatitis. All cases were hepatitis B surface antigen negative. Covalently closed circular HBV genomes, HBV transcripts, and viral integrated forms were investigated in cases of HCC found positive for occult HBV. Math Eq: Viral DNA was detected in 68 of 107 cases of HCC (63.5%) and in 63 of 192 cases of chronic hepatitis (32.8%) (P < 0.0001; odds ratio, 3.6; 95% confidence interval, 2.2–5.9). The significant association of occult HBV with HCC was irrespective of age, sex, and contemporary hepatitis C virus infection. Both integrated viral DNA and covalently closed circular HBV genomes were detected in patients with occult HBV. Moreover, the presence of free HBV genomes was associated with persistence of viral transcription and replication. Math Eq: Our findings provide clear evidence that occult HBV is a risk factor for development of HCC and show that the potential mechanisms whereby overt HBV might induce tumor formation are mostly maintained in cases of occult infection.

1 August 2014 in Journal of Hepatology
Verified
Journal Article
Open access
TPTeresa Pollicino
Teresa Pollicino
Irene CacciolaIrene Cacciola
Irene Cacciola
FSFrancesca Saffioti
Francesca Saffioti
GRGiovanni Raimondo
Giovanni Raimondo
The emergence and takeover of hepatitis B virus (HBV) variants carrying mutation(s) in the preS/S genomic region is a fairly frequent event that may occur spontaneously or may be the consequence of immunoprophylaxis or antiviral treatments. Selection of preS/S mutants may have relevant pathobiological and clinical implications. Both experimental data and studies in humans show that several specific mutations in the preS/S gene may induce an imbalance in the synthesis of the surface proteins and their consequent retention within the endoplasmic reticulum (ER) of the hepatocytes. The accumulation of mutated surface proteins may cause ER stress with the consequent induction of oxidative DNA damage and genomic instability. Viral mutants with antigenically modified surface antigen may be potentially infectious to immune-prophylaxed patients and may account for cases of occult HBV infection. In addition, preS/S variants were reported to be associated with cases of fulminant hepatitis as well as of fibrosing cholestatic hepatitis, and they are associated with cirrhosis and hepatocellular carcinoma development.

1 August 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
CCCiro Celsa
Ciro Celsa
VCVincenza Calvaruso
Vincenza Calvaruso
SPSalvatore Petta
Salvatore Petta
Irene CacciolaIrene Cacciola
Irene Cacciola
CCCalogero Cammà
Calogero Cammà

9 August 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
Giuseppe CabibboGiuseppe Cabibbo
Giuseppe Cabibbo
SPSalvatore Petta
Salvatore Petta
VCVincenza Calvaruso
Vincenza Calvaruso
Irene CacciolaIrene Cacciola
Irene Cacciola
MCM. R. Cannavò
M. R. Cannavò
R(Rete Sicilia Selezione Terapia – Hcv (Resist‐Hcv)
Rete Sicilia Selezione Terapia – Hcv (Resist‐Hcv)
Summary: Background: Data on HCV‐related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct‐acting antivirals (DAAs), are equivocal.Aim: To assess the risk of HCC early recurrence after DAAs exposure in a large prospective cohort of HCV‐cirrhotic patients with previous successfully treated HCC, also looking for risk factors for cancer early recurrence.Methods: We enrolled 143 consecutive patients with complete response after curative treatment of HCC, subsequently treated with DAAs and monitored by the web‐based RESIST‐HCV database. Clinical, biological, and virological data were collected. The primary endpoint was the probability of HCC early recurrence from DAA starting by Kaplan‐Meier method.Results: Eighty‐six per cent of patients were in Child‐Pugh class A and 76% of patients were BCLC A. Almost all patients (96%) achieved sustained virological response. Twenty‐four HCC recurrences were observed, with nodular or infiltrative pattern in 83% and 17% of patients, respectively. The 6‐, 12‐ and 18‐month HCC recurrence rates were 12%, 26.6% and 29.1%, respectively. Main tumour size and history of prior HCC recurrence were independent risk factors for HCC recurrence by Cox multivariate model.Conclusions: Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA‐untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality.